FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS WEST PALM BEACH, FLORIDA, June 27, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has designated a new series of its preferred stock (Series E Cumulative Redeemable Secured Preferred Stock e (the “Series E Preferred Stock”)) and filed the series’ certificate of designation with the Secretary of State of Delaware. The newly designated series of preferred stock includes: (i) a stated value of $25.00 per share, (ii) a 2.5% per a...
FOXO TECHNOLOGIES INC.’S CRITICAL ACCESS HOSPITAL ANNOUNCES NEW WOUND CARE SERVICES OFFERING WEST PALM BEACH, FLORIDA, June 17, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its critical access hospital, Big South Fork Medical Center located in Oneida, Tennessee, has commenced offering wound care services to patients both on an inpatient and outpatient basis. The hospital has experienced a growing demand for wound care services in its market service area, particularly for diabetic patients who have wounds often charact...
A director at Paycom Software Inc sold 1,500 shares at 249.959USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
FOXO TECHNOLOGIES INC. CREATES ACQUISITION VEHICLE AND APPOINTS NEW INTERIM CFO WEST PALM BEACH, FLORIDA, June 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it formed a new, wholly-owned subsidiary intended to be used to acquire identified acquisition targets in the healthcare services and related sectors. On June 13, 2025, the Company formed FOXO Acquisition Corporation, a Florida corporation, for the purpose of acquiring targeted acquisitions. The Company also intends to create a new series of non-convertible pr...
FOXO TECHNOLOGIES INC. COMPLETES EQUITY FUNDING AGREEMENT WEST PALM BEACH, FLORIDA, June 04, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has executed an agreement to issue 1,650 of its Series A Cumulative Convertible Redeemable Preferred Stock (“Series A Preferred Stock”) for net proceeds of $1,500,000. On June 3, 2025, FOXO”) entered into a Securities Purchase Agreement with certain existing institutional investors of the Company. The Securities Purchase Agreement provides for the issuance of up to 1,650 shares ...
FOXO TECHNOLOGIES INC.’S CRITICAL ACCESS HOSPITAL ANNOUNCES EXPANSION OF SERVICES TO INCLUDE WOUND CARE WEST PALM BEACH, FLORIDA, May 19, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its critical access hospital, Big South Fork Medical Center in Oneida, Tennessee, is expanding its services by offering wound care services to patients on an inpatient and outpatient basis. The hospital intends to commence such services on June 2, 2025, and expects to complete the reconfiguration of certain space at the hospital and addit...
FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY REACHES KEY OPERATIONAL MILESTONES WEST PALM BEACH, FLORIDA, May 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has reached key patient care milestones. Since operations commenced at its Oneida, Tennessee location in August 2023, the facility has seen over 400 patients and has served patients for over 5,000 care days. Robert Merritt, Chief of Executive Officer of Myrtle stated, “We are excited abou...
FOXO TECHNOLOGIES INC. ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT West Palm Beach, April 29, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), today announced that effective 4.01pm Eastern Time, on April 28, 2025, (the “Effective Time”), the Company completed a 1 for 10 reverse stock split of its outstanding common stock. The Company’s common stock will open for trading on Tuesday April 29, 2025, on a post-split basis and continue to trade under the symbol FOXO. As a result of the reverse split, every 10 shares of the Company’s common stock...
FOXO TECHNOLOGIES INC. ANNOUNCES REVERSE STOCK SPLIT FLORIDA, April 17, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), today announced that its Board of Directors has approved a 1 for 10 reverse stock split of the Company’s Class A common stock, par value $0.0001 (the “Common Stock”). The reverse stock split will become effective at 4:01pm ET on April 28, 2025 (the “Effective Time”). The Common Stock will begin trading on a split-adjusted basis on the NYSE American under the same trading symbol “FOXO” when the market opens on April 29, 202...
FOXO TECHNOLOGIES INC. ANNOUNCES FILING OF ITS ANNUAL REPORT ON FORM 10-K WEST PALM BEACH, FL, April 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”) announces that it has filed its Annual Report on Form 10-K on April 15, 2025. Pursuant to the disclosure requirements of the NYSE American Company Guidelines Sections 401(h) and 610(b), FOXO is reporting that its audited financial statements for the fiscal year ended December 31, 2024, included in FOXO’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, contains an audit o...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01 STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trendi...
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the preliminary immune response data from ...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from dat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.